GHK-Cu Price in Australia: A$69.99 for 50mg
Part of the Compound Research topic cluster · editorial policy
The current Pillar Research price for in-stock GHK-Cu 50mg (copper tripeptide) is A$69.99 per vial. What the price covers, what the batch report actually measured, and how to compare copper-peptide offers without being misled by the milligram figure.
Current GHK-Cu price in Australia
Pillar Research lists GHK-Cu 50mg at A$69.99 per vial, held and dispatched from Australian stock. The separate GHK-Cu 100mg listing shows its own price and documentation. The product page is the live source for price and availability; this article explains what sits behind the number.
Why the milligram figure needs reading carefully
GHK-Cu is not a plain peptide. It is a tripeptide (glycyl-L-histidyl-L-lysine) in complex with copper, so a vial contains peptide plus co-ordinated copper, and the two are weighed differently depending on what the label is describing. This is the single most common source of confusion when comparing copper-peptide prices between suppliers.
The released Pillar Research batch makes the distinction explicit. Batch 2026-210952 reports a net content of 71.02mg GHK-Cu (59.09mg GHK; 11.93mg copper). In other words, the labelled 50mg refers to the peptide portion, while the total complex in the vial weighs more once the co-ordinated copper is counted.
What the listed price includes
- Declared strength: 50mg of lyophilised GHK-Cu research material per vial.
- Reported purity: 99.815% for batch 2026-210952, analysed by Janoshik.
- Identity result: Sample reported as GHK-Cu, reported separately from the purity figure.
- Stated composition: 71.02mg GHK-Cu (59.09mg GHK; 11.93mg copper), so the peptide and copper fractions are both documented.
- Batch record: a batch-specific GHK-Cu certificate of analysis tied to the material supplied.
- Local fulfilment: Australian stock and dispatch, not international transshipment.
50mg or 100mg: which listing to price against
Compare GHK-Cu 50mg at A$69.99 with GHK-Cu 100mg at A$109.99. These are separate vial presentations with separate product URLs. Select the required amount of research material, then check the documentation for that exact strength.
The milligram figure describes the material supplied in one vial. It is not a dosing instruction. Each product page is the current source for its price and ordering options. Research Use Only.
How to compare GHK-Cu offers
Start with price per stated milligram, then verify that the stated milligram means the same thing on both pages. After that, the checks are the same as for any research peptide.
- Does the label distinguish the peptide mass from the copper-complex mass?
- Is the price in AUD, and is any shipping charge identified separately?
- Is the batch report dated, numbered, and matched to the vial being sold?
- Are identity and purity treated as two separate analytical questions?
- Is the stock genuinely held in Australia, or is the page collecting preorders?
The COA review checklist and the identity-versus-purity guide set out a method-aware way to document those checks.
What the research literature covers
GHK-Cu has been studied for copper co-ordination and for its behaviour in skin-model systems. Published work includes copper-binding characterisation in a zebrafish model[1] and in-vitro penetration work on a copper tripeptide in skin preparations.[2] These are laboratory findings about the molecule and its handling, not evidence of outcomes in people.
For the fuller research picture, including the historical characterisation literature, see the GHK-Cu research overview.
Price, stock and dispatch can change
Price-intent pages go stale when a figure is copied into several places at once. Pillar Research treats the product record as the source of truth and links this article straight back to it. Verify the live A$69.99 price, stock label and batch COA on the product page before ordering.
Compliance reminder
GHK-Cu is supplied for research and educational purposes only. It is not listed on the Australian Register of Therapeutic Goods (ARTG) and must not be consumed by humans or animals. All experimental use should follow institutional safety guidelines and relevant regulations.
Comparing copper-peptide options? View GHK-Cu in Australia. For related research, see the GHK-Cu research overview and the KLOW blend identity review, which covers GHK-Cu as a blend component.
Primary sources
Links lead to the original paper, DOI record, or open-access full text where available.
This compound is supplied for in vitro laboratory and educational research only. It is not listed on the Australian Register of Therapeutic Goods (ARTG) and is not a therapeutic good under the Therapeutic Goods Act 1989 (Cth). Not for human or animal consumption, therapeutic use, or diagnostic procedures. By purchasing, you confirm you are a qualified researcher or acting on behalf of a licensed research facility, and you assume full responsibility for the safe handling, storage, and lawful use of this compound.